查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1597564

全球抗体/重组蛋白 CDMO 市场：按类型、来源类型、生产规模、应用、最终用户、地区 - 趋势分析、竞争格局、预测（2019-2030）

Antibody and Recombinant Protein CDMO Market, By Type; By Source Type; By Scale of Production; By Application; By End User, By Region, Global Trend Analysis, Competitive Landscape & Forecast, 2019-2030
出版日期: | 出版商: Blueweave Consulting | 英文 530 Pages | 商品交期: 2-3个工作天内

价格
简介目录

2030年全球抗体和重组蛋白CDMO市场规模预计将超过350亿美元

由于对合约生物製药开发和製造服务的需求不断增加，以及生技药品製造过程的复杂性不断增加，全球抗体和重组蛋白 CDMO 市场正在蓬勃发展。

领先的策略咨询和市场研究公司 BlueWeave Consulting 在最近的一项研究中估计，2023 年全球抗体和重组蛋白 CDMO 市场规模为 167 亿美元。 BlueWeave预测，2024-2030年期间，全球抗体和重组蛋白CDMO市场将以11.2%的复合年增长率成长，到2030年达到354亿美元。全球抗体和重组蛋白 CDMO 市场的关键成长要素是对生技药品和重组蛋白治疗药物的需求不断增长。此外，包括糖尿病和癌症在内的各种慢性疾病的盛行率上升、科学突破以及生物製药领域投资的增加将推动预测期内全球抗体和重组蛋白 CDMO 市场的成长。

机会：重大收购和併购

许多受託製造厂商(CDMO) 正在进行併购以扩展其现有能力。小型公司正在合併以利用技术和平台，而中型公司则专注于透过这些策略联盟实现管道多元化。例如，美国CDMO公司Curia最近收购了製剂和灌装加工公司完整性 Bio。另一个例子是，Delpharm 宣布将从Astellas Pharma 手中收购荷兰 Meppel 製药厂，从而加强其在该国的 CDMO 地位。在分析期间，此类发展预计将为全球抗体和重组蛋白 CDMO 市场提供利润丰厚的成长机会。

地缘政治紧张局势加剧对全球抗体和重组蛋白 CDMO 市场的影响

关键地区国家之间地缘政治紧张局势的加剧可能会为全球抗体和重组蛋白 CDMO 市场带来前所未有的挑战。地缘政治紧张局势对市场运作的一个重大影响是供应链的中断，使得获得製造抗体和重组蛋白所需的原料和试剂变得更加困难。许多出口国可能会施加关税和贸易限制，这可能会使 CDMO 的采购技术变得更加困难。由于衝突或加强安全措施而导致的物流和运输延误可能会影响预定的产品交付。紧张局势升级可能导致法律规范收紧，进而影响 CDMO 开展跨国业务的能力。

治疗药物领域占据大部分市场占有率

治疗药物领域在全球抗体和重组蛋白 CDMO 市场中占有最大份额。生活方式的改变和老年人口的增加正在增加各种慢性疾病的盛行率，增加了对用于治疗目的的重组蛋白疗法的需求。重组蛋白疗法广泛用于治疗各种类型的癌症。随着全球癌症盛行率的不断增加，对重组蛋白的需求预计只会增加。

北美在全球市场占据主导地位

北美主导全球抗体和重组蛋白 CDMO 市场。该地区的市场扩张得到了美国和加拿大强大的医疗保健系统以及重要生物技术和製药公司集中的支持。然而，亚太地区预计在预测期内将出现显着成长。亚太地区抗体和重组蛋白 CDMO 市场预计将受到该地区不断增长的医疗保健支出和不断增加的研发倡议的推动。

竞争格局

全球抗体和重组蛋白 CDMO 市场的主要行业参与者包括 Batavia Biosciences、Grifols、Cerbios-Pharma SA、HALIX、Biovian Oy、Catalent、Goodwin Biotechnology、Cerbios-Pharma SA、Gene Universal Inc.、Eurogentec、MabPlex International、Etinpro（北京）有限公司等

为了进一步增加市场占有率，这些公司正在采取各种策略，例如併购、伙伴关係、合资、授权合约和新产品发布。

该报告的详细分析提供了有关成长潜力、未来趋势和全球抗体和重组蛋白 CDMO 市场的资讯。它还涵盖了推动市场总规模预测的因素。该报告致力于提供全球抗体和重组蛋白 CDMO 市场的最新技术趋势以及产业见解，以帮助决策者做出策略决策。此外，我们也分析了市场的成长动力、挑战和竞争力。

目录

第一章 研究框架

第 2 章执行摘要

第三章 全球抗体与重组蛋白CDMO市场洞察

  • 产业价值链分析
  • DROC分析
    • 生长促进因子
      • 生物製药需求增加
      • 复杂的製造工艺
      • 生物技术的不断进步
    • 抑制因素
      • 监管障碍高
      • 保护智慧财产权
      • 容量限制
    • 机会
      • 医疗基础设施不断发展的新兴国家
      • 个性化医疗的兴起
      • 细胞和基因治疗的快速发展
    • 任务
      • 确保生物製药的品质和一致性
      • 竞争加剧和成本压力
  • 科技进步/最新趋势
  • 法律规范
  • 波特五力分析

第四章 全球抗体/重组蛋白CDMO市场：行销策略

第五章 全球抗体/重组蛋白CDMO市场：价格分析

第六章全球抗体/重组蛋白 CDMO 市场：区域分析

  • 全球抗体/重组蛋白 CDMO 市场：区域分析 (2023)
  • 全球抗体/重组蛋白CDMO市场：市场吸引力分析（2019-2030）

第七章 全球抗体/重组蛋白CDMO市场概况

  • 市场规模及预测（2019-2030）
    • 按金额
  • 市场占有率及预测
    • 按类型
      • 抗体CDMO
      • 重组蛋白CDMO
    • 按来源类型
      • 哺乳动物的
      • 微生物
      • 其他的
    • 按生产规模
      • 临床製造
      • 商业製造
    • 按用途
      • 治疗药物
      • 研究与开发
      • 诊断
    • 按最终用户
      • 製药和生物技术公司
      • 学术研究所
      • 合约研究组织（CRO）
    • 按地区
      • 北美洲
      • 欧洲
      • 亚太地区 (APAC)
      • 拉丁美洲 (LATAM)
      • 中东和非洲 (MEA)

第八章 北美抗体/重组蛋白CDMO市场

  • 市场规模及预测（2019-2030）
    • 按金额
  • 市场占有率及预测
    • 按类型
    • 按来源类型
    • 按生产规模
    • 按用途
    • 按最终用户
    • 按国家/地区
      • 美国
      • 加拿大

第九章 欧洲抗体/重组蛋白CDMO市场

  • 市场规模及预测（2019-2030）
    • 按金额
  • 市场占有率及预测
    • 按类型
    • 按来源类型
    • 按生产规模
    • 按用途
    • 按最终用户
    • 按国家/地区
      • 德国
      • 英国
      • 义大利
      • 法国
      • 西班牙
      • 比利时
      • 俄罗斯
      • 荷兰
      • 其他欧洲国家

第十章亚太抗体/重组蛋白CDMO市场

  • 市场规模及预测（2019-2030）
    • 按金额
  • 市场占有率及预测
    • 按类型
    • 按来源类型
    • 按生产规模
    • 按用途
    • 按最终用户
    • 按国家/地区
      • 中国
      • 印度
      • 日本
      • 韩国
      • 澳洲和纽西兰
      • 印尼
      • 马来西亚
      • 新加坡
      • 越南
      • 其他亚太地区

第十一章拉丁美洲抗体/重组蛋白CDMO市场

  • 市场规模及预测（2019-2030）
    • 按金额
  • 市场占有率及预测
    • 按类型
    • 按来源类型
    • 按生产规模
    • 按用途
    • 按最终用户
    • 按国家/地区
      • 巴西
      • 墨西哥
      • 阿根廷
      • 秘鲁
      • 其他拉丁美洲

第十二章中东与非洲抗体/重组蛋白CDMO市场

  • 市场规模及预测（2019-2030）
    • 按金额
  • 市场占有率及预测
    • 按类型
    • 按来源类型
    • 按生产规模
    • 按用途
    • 按最终用户
    • 按国家/地区
      • 沙乌地阿拉伯
      • 阿拉伯聯合大公国
      • 卡达
      • 科威特
      • 南非
      • 奈及利亚
      • 阿尔及利亚
      • 其他中东/非洲

第十三章竞争格局

  • 主要企业/产品列表
  • 全球抗体/重组蛋白CDMO企业市场占有率分析（2023年）
  • 竞争基准化分析：管理参数
  • 重大策略发展（合併、收购、联盟等）

第14章 地缘政治紧张局势升级对全球抗体和重组蛋白CDMO市场的影响

第十五章 公司简介（公司简介、财务矩阵、竞争格局、关键人员、主要竞争对手、联络地址、策略展望、SWOT分析）

  • Batavia Biosciences
  • Grifols
  • Cerbios-Pharma SA
  • HALIX
  • Biovian Oy
  • Catalent
  • Goodwin Biotechnology
  • Cerbios-Pharma SA
  • Gene Universal Inc.
  • Eurogentec
  • MabPlex International
  • Etinpro（Beijing）Co
  • 其他主要企业

第十六章 主要策略建议

第十七章调查方法

简介目录
Product Code: BWC24833

Global Antibody and Recombinant Protein CDMO Market to Cross USD 35 Billion by 2030

Global Antibody and Recombinant Protein CDMO Market is flourishing because of a rising demand for biopharma contract development and manufacturing services and increasingly complex processes involved in producing biologics.

BlueWeave Consulting, a leading strategic consulting and market research firm, in its recent study, estimated Global Antibody and Recombinant Protein CDMO Market size at USD 16.70 billion in 2023. During the forecast period between 2024 and 2030, BlueWeave expects Global Antibody and Recombinant Protein CDMO Market size to expand at a CAGR of 11.2% reaching a value of USD 35.40 billion by 2030. Major growth factors for Global Antibody and Recombinant Protein CDMO Market include an increasing need for biologics and recombinant protein therapies. Over the forecast period, it is also expected that the growth of Global Antibody and Recombinant Protein CDMO Market will be spurred by the rising incidence of various chronic illnesses, including diabetes and cancer, scientific breakthroughs, and rising investments biopharmaceutical sector.

Opportunity - Major Acquisitions and Mergers

Many contract development and manufacturing organizations (CDMOs) are entering into mergers and acquisitions to expand their existing capacities. Small companies merge to leverage technology and platforms, while mid-size companies focus on diversifying pipelines through these strategic alliances. For instance, Curia, an American CDMO company, recently acquired Integrity Bio, a formulation and fill-finish company. In another example, Delpharm announced the acquisition of the Meppel pharmaceutical manufacturing facility in the Netherlands from Astellas to strengthen CDMO's position in the country. Such developments are anticipated to provide lucrative growth opportunities to global antibody and recombinant protein CDMO market during the period in analysis.

Impact of Escalating Geopolitical Tensions on Global Antibody and Recombinant Protein CDMO Market

Intensifying geopolitical tensions among countries spreading across the major regions could bring unprecedented challenges for Global Antibody and Recombinant Protein CDMO Market. A significant effect of geopolitical tensions on market operations is supply chain disruption, which makes it more difficult to get the necessary raw materials and reagents for the manufacturing of antibodies and recombinant proteins. Many exporting nations may apply tariffs or trade restrictions, which might make CDMOs' sourcing techniques more difficult. Product delivery on schedule may be impacted by delays in logistics and transportation caused by conflicts or increased security measures. Increased tensions may result in more stringent regulatory frameworks, which would affect CDMOs' capacity to conduct cross-border operations.

Therapeutics Segment Accounts for Major Market Share

The therapeutics segment holds the largest share of Global Antibody and Recombinant Protein CDMO Market. The growing prevalence of various chronic diseases owing to changing lifestyles and the rising geriatric populations is fueling the demand for recombinant protein therapeutics for treatment purposes. Recombinant protein therapeutics are widely used to treat various types of cancer. With the increasing prevalence of cancer worldwide, the demand for recombinant proteins is projected to rise only.

North America Holds Leadership Position in Global Market

North America dominates Global Antibody and Recombinant Protein CDMO Market. Expansion of the regional market is aided by the concentration of significant biotechnology and pharmaceutical firms as well as the strong healthcare systems in United States and Canada. However, over the forecast period, the Asia Pacific region is expected to register a significant growth rate. The Asia Pacific Antibody and Recombinant Protein CDMO Market is expected to be driven by the region's growing healthcare spending as well as an increase in research and development initiatives.

Competitive Landscape

Major industry players of Global Antibody and Recombinant Protein CDMO Market include Batavia Biosciences, Grifols, Cerbios-Pharma SA, HALIX, Biovian Oy, Catalent, Goodwin Biotechnology, Cerbios-Pharma SA, Gene Universal Inc., Eurogentec, MabPlex International, and Etinpro (Beijing) Co.

To further enhance their market share, these companies employ various strategies, including mergers and acquisitions, partnerships, joint ventures, license agreements, and new product launches.

The in-depth analysis of the report provides information about growth potential, upcoming trends, and Global Antibody and Recombinant Protein CDMO Market. It also highlights the factors driving forecasts of total market size. The report promises to provide recent technology trends in Global Antibody and Recombinant Protein CDMO Market and industry insights to help decision-makers make sound strategic decisions. Furthermore, the report also analyzes the growth drivers, challenges, and competitive dynamics of the market.

Table of Contents

1. Research Framework

  • 1.1. Research Objective
  • 1.2. Product Overview
  • 1.3. Market Segmentation

2. Executive Summary

3. Global Antibody and Recombinant Protein CDMO Market Insights

  • 3.1. Industry Value Chain Analysis
  • 3.2. DROC Analysis
    • 3.2.1. Growth Drivers
      • 3.2.1.1. Increasing Demand for Biologics
      • 3.2.1.2. Complex Manufacturing Processes
      • 3.2.1.3. Continuous Advancements in Biotechnology
    • 3.2.2. Restraints
      • 3.2.2.1. High Regulatory Hurdles
      • 3.2.2.2. Protecting Intellectual Property Rights
      • 3.2.2.3. Capacity Constraints
    • 3.2.3. Opportunities
      • 3.2.3.1. Developing Countries with Growing Healthcare Infrastructure
      • 3.2.3.2. Rise of Personalized Medicine
      • 3.2.3.3. Rapid Development of Cell and Gene Therapies
    • 3.2.4. Challenges
      • 3.2.4.1. Ensuring the Quality and Consistency of Biologic Products
      • 3.2.4.2. Increasing Competition and Cost Pressures
  • 3.3. Technological Advancements/Recent Developments
  • 3.4. Regulatory Framework
  • 3.5. Porter's Five Forces Analysis
    • 3.5.1. Bargaining Power of Suppliers
    • 3.5.2. Bargaining Power of Buyers
    • 3.5.3. Threat of New Entrants
    • 3.5.4. Threat of Substitutes
    • 3.5.5. Intensity of Rivalry

4. Global Antibody and Recombinant Protein CDMO Market: Marketing Strategies

5. Global Antibody and Recombinant Protein CDMO Market: Pricing Analysis

6. Global Antibody and Recombinant Protein CDMO Market: Geographical Analysis

  • 6.1. Global Antibody and Recombinant Protein CDMO Market, Geographical Analysis, 2023
  • 6.2. Global Antibody and Recombinant Protein CDMO Market, Market Attractiveness Analysis, 2019-2030

7. Global Antibody and Recombinant Protein CDMO Market Overview

  • 7.1. Market Size & Forecast, 2019-2030
    • 7.1.1. By Value (USD Billion)
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
      • 7.2.1.1. Antibody CDMO
      • 7.2.1.2. Recombinant Protein CDMO
    • 7.2.2. By Source Type
      • 7.2.2.1. Mammalian
      • 7.2.2.2. Microbial
      • 7.2.2.3. Others
    • 7.2.3. By Scale of Production
      • 7.2.3.1. Clinical Manufacturing
      • 7.2.3.2. Commercial Manufacturing
    • 7.2.4. By Application
      • 7.2.4.1. Therapeutics
      • 7.2.4.2. Research & Development
      • 7.2.4.3. Diagnostics
    • 7.2.5. By End User
      • 7.2.5.1. Pharmaceutical & Biotechnology Companies
      • 7.2.5.2. Academic & Research Institutes
      • 7.2.5.3. Contract Research Organizations (CROs)
    • 7.2.6. By Region
      • 7.2.6.1. North America
      • 7.2.6.2. Europe
      • 7.2.6.3. Asia Pacific (APAC)
      • 7.2.6.4. Latin America (LATAM)
      • 7.2.6.5. Middle East and Africa (MEA)

8. North America Antibody and Recombinant Protein CDMO Market

  • 8.1. Market Size & Forecast, 2019-2030
    • 8.1.1. By Value (USD Billion)
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Source Type
    • 8.2.3. By Scale of Production
    • 8.2.4. By Application
    • 8.2.5. By End User
    • 8.2.6. By Country
      • 8.2.6.1. United States
      • 8.2.6.1.1. By Type
      • 8.2.6.1.2. By Source Type
      • 8.2.6.1.3. By Scale of Production
      • 8.2.6.1.4. By Application
      • 8.2.6.1.5. By End User
      • 8.2.6.2. Canada
      • 8.2.6.2.1. By Type
      • 8.2.6.2.2. By Source Type
      • 8.2.6.2.3. By Scale of Production
      • 8.2.6.2.4. By Application
      • 8.2.6.2.5. By End User

9. Europe Antibody and Recombinant Protein CDMO Market

  • 9.1. Market Size & Forecast, 2019-2030
    • 9.1.1. By Value (USD Billion)
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Source Type
    • 9.2.3. By Scale of Production
    • 9.2.4. By Application
    • 9.2.5. By End User
    • 9.2.6. By Country
      • 9.2.6.1. Germany
      • 9.2.6.1.1. By Type
      • 9.2.6.1.2. By Source Type
      • 9.2.6.1.3. By Scale of Production
      • 9.2.6.1.4. By Application
      • 9.2.6.1.5. By End User
      • 9.2.6.2. United Kingdom
      • 9.2.6.2.1. By Type
      • 9.2.6.2.2. By Source Type
      • 9.2.6.2.3. By Scale of Production
      • 9.2.6.2.4. By Application
      • 9.2.6.2.5. By End User
      • 9.2.6.3. Italy
      • 9.2.6.3.1. By Type
      • 9.2.6.3.2. By Source Type
      • 9.2.6.3.3. By Scale of Production
      • 9.2.6.3.4. By Application
      • 9.2.6.3.5. By End User
      • 9.2.6.4. France
      • 9.2.6.4.1. By Type
      • 9.2.6.4.2. By Source Type
      • 9.2.6.4.3. By Scale of Production
      • 9.2.6.4.4. By Application
      • 9.2.6.4.5. By End User
      • 9.2.6.5. Spain
      • 9.2.6.5.1. By Type
      • 9.2.6.5.2. By Source Type
      • 9.2.6.5.3. By Scale of Production
      • 9.2.6.5.4. By Application
      • 9.2.6.5.5. By End User
      • 9.2.6.6. Belgium
      • 9.2.6.6.1. By Type
      • 9.2.6.6.2. By Source Type
      • 9.2.6.6.3. By Scale of Production
      • 9.2.6.6.4. By Application
      • 9.2.6.6.5. By End User
      • 9.2.6.7. Russia
      • 9.2.6.7.1. By Type
      • 9.2.6.7.2. By Source Type
      • 9.2.6.7.3. By Scale of Production
      • 9.2.6.7.4. By Application
      • 9.2.6.7.5. By End User
      • 9.2.6.8. The Netherlands
      • 9.2.6.8.1. By Type
      • 9.2.6.8.2. By Source Type
      • 9.2.6.8.3. By Scale of Production
      • 9.2.6.8.4. By Application
      • 9.2.6.8.5. By End User
      • 9.2.6.9. Rest of Europe
      • 9.2.6.9.1. By Type
      • 9.2.6.9.2. By Source Type
      • 9.2.6.9.3. By Scale of Production
      • 9.2.6.9.4. By Application
      • 9.2.6.9.5. By End User

10. Asia Pacific Antibody and Recombinant Protein CDMO Market

  • 10.1. Market Size & Forecast, 2019-2030
    • 10.1.1. By Value (USD Billion)
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Source Type
    • 10.2.3. By Scale of Production
    • 10.2.4. By Application
    • 10.2.5. By End User
    • 10.2.6. By Country
      • 10.2.6.1. China
      • 10.2.6.1.1. By Type
      • 10.2.6.1.2. By Source Type
      • 10.2.6.1.3. By Scale of Production
      • 10.2.6.1.4. By Application
      • 10.2.6.1.5. By End User
      • 10.2.6.2. India
      • 10.2.6.2.1. By Type
      • 10.2.6.2.2. By Source Type
      • 10.2.6.2.3. By Scale of Production
      • 10.2.6.2.4. By Application
      • 10.2.6.2.5. By End User
      • 10.2.6.3. Japan
      • 10.2.6.3.1. By Type
      • 10.2.6.3.2. By Source Type
      • 10.2.6.3.3. By Scale of Production
      • 10.2.6.3.4. By Application
      • 10.2.6.3.5. By End User
      • 10.2.6.4. South Korea
      • 10.2.6.4.1. By Type
      • 10.2.6.4.2. By Source Type
      • 10.2.6.4.3. By Scale of Production
      • 10.2.6.4.4. By Application
      • 10.2.6.4.5. By End User
      • 10.2.6.5. Australia & New Zealand
      • 10.2.6.5.1. By Type
      • 10.2.6.5.2. By Source Type
      • 10.2.6.5.3. By Scale of Production
      • 10.2.6.5.4. By Application
      • 10.2.6.5.5. By End User
      • 10.2.6.6. Indonesia
      • 10.2.6.6.1. By Type
      • 10.2.6.6.2. By Source Type
      • 10.2.6.6.3. By Scale of Production
      • 10.2.6.6.4. By Application
      • 10.2.6.6.5. By End User
      • 10.2.6.7. Malaysia
      • 10.2.6.7.1. By Type
      • 10.2.6.7.2. By Source Type
      • 10.2.6.7.3. By Scale of Production
      • 10.2.6.7.4. By Application
      • 10.2.6.7.5. By End User
      • 10.2.6.8. Singapore
      • 10.2.6.8.1. By Type
      • 10.2.6.8.2. By Source Type
      • 10.2.6.8.3. By Scale of Production
      • 10.2.6.8.4. By Application
      • 10.2.6.8.5. By End User
      • 10.2.6.9. Vietnam
      • 10.2.6.9.1. By Type
      • 10.2.6.9.2. By Source Type
      • 10.2.6.9.3. By Scale of Production
      • 10.2.6.9.4. By Application
      • 10.2.6.9.5. By End User
      • 10.2.6.10. Rest of APAC
      • 10.2.6.10.1. By Type
      • 10.2.6.10.2. By Source Type
      • 10.2.6.10.3. By Scale of Production
      • 10.2.6.10.4. By Application
      • 10.2.6.10.5. By End User

11. Latin America Antibody and Recombinant Protein CDMO Market

  • 11.1. Market Size & Forecast, 2019-2030
    • 11.1.1. By Value (USD Billion)
  • 11.2. Market Share & Forecast
    • 11.2.1. By Type
    • 11.2.2. By Source Type
    • 11.2.3. By Scale of Production
    • 11.2.4. By Application
    • 11.2.5. By End User
    • 11.2.6. By Country
      • 11.2.6.1. Brazil
      • 11.2.6.1.1. By Type
      • 11.2.6.1.2. By Source Type
      • 11.2.6.1.3. By Scale of Production
      • 11.2.6.1.4. By Application
      • 11.2.6.1.5. By End User
      • 11.2.6.2. Mexico
      • 11.2.6.2.1. By Type
      • 11.2.6.2.2. By Source Type
      • 11.2.6.2.3. By Scale of Production
      • 11.2.6.2.4. By Application
      • 11.2.6.2.5. By End User
      • 11.2.6.3. Argentina
      • 11.2.6.3.1. By Type
      • 11.2.6.3.2. By Source Type
      • 11.2.6.3.3. By Scale of Production
      • 11.2.6.3.4. By Application
      • 11.2.6.3.5. By End User
      • 11.2.6.4. Peru
      • 11.2.6.4.1. By Type
      • 11.2.6.4.2. By Source Type
      • 11.2.6.4.3. By Scale of Production
      • 11.2.6.4.4. By Application
      • 11.2.6.4.5. By End User
      • 11.2.6.5. Rest of LATAM
      • 11.2.6.5.1. By Type
      • 11.2.6.5.2. By Source Type
      • 11.2.6.5.3. By Scale of Production
      • 11.2.6.5.4. By Application
      • 11.2.6.5.5. By End User

12. Middle East & Africa Antibody and Recombinant Protein CDMO Market

  • 12.1. Market Size & Forecast, 2019-2030
    • 12.1.1. By Value (USD Billion)
  • 12.2. Market Share & Forecast
    • 12.2.1. By Type
    • 12.2.2. By Source Type
    • 12.2.3. By Scale of Production
    • 12.2.4. By Application
    • 12.2.5. By End User
    • 12.2.6. By Country
      • 12.2.6.1. Saudi Arabia
      • 12.2.6.1.1. By Type
      • 12.2.6.1.2. By Source Type
      • 12.2.6.1.3. By Scale of Production
      • 12.2.6.1.4. By Application
      • 12.2.6.1.5. By End User
      • 12.2.6.2. UAE
      • 12.2.6.2.1. By Type
      • 12.2.6.2.2. By Source Type
      • 12.2.6.2.3. By Scale of Production
      • 12.2.6.2.4. By Application
      • 12.2.6.2.5. By End User
      • 12.2.6.3. Qatar
      • 12.2.6.3.1. By Type
      • 12.2.6.3.2. By Source Type
      • 12.2.6.3.3. By Scale of Production
      • 12.2.6.3.4. By Application
      • 12.2.6.3.5. By End User
      • 12.2.6.4. Kuwait
      • 12.2.6.4.1. By Type
      • 12.2.6.4.2. By Source Type
      • 12.2.6.4.3. By Scale of Production
      • 12.2.6.4.4. By Application
      • 12.2.6.4.5. By End User
      • 12.2.6.5. South Africa
      • 12.2.6.5.1. By Type
      • 12.2.6.5.2. By Source Type
      • 12.2.6.5.3. By Scale of Production
      • 12.2.6.5.4. By Application
      • 12.2.6.5.5. By End User
      • 12.2.6.6. Nigeria
      • 12.2.6.6.1. By Type
      • 12.2.6.6.2. By Source Type
      • 12.2.6.6.3. By Scale of Production
      • 12.2.6.6.4. By Application
      • 12.2.6.6.5. By End User
      • 12.2.6.7. Algeria
      • 12.2.6.7.1. By Type
      • 12.2.6.7.2. By Source Type
      • 12.2.6.7.3. By Scale of Production
      • 12.2.6.7.4. By Application
      • 12.2.6.7.5. By End User
      • 12.2.6.8. Rest of MEA
      • 12.2.6.8.1. By Type
      • 12.2.6.8.2. By Source Type
      • 12.2.6.8.3. By Scale of Production
      • 12.2.6.8.4. By Application
      • 12.2.6.8.5. By End User

13. Competitive Landscape

  • 13.1. List of Key Players and Their Offerings
  • 13.2. Global Antibody and Recombinant Protein CDMO Company Market Share Analysis, 2023
  • 13.3. Competitive Benchmarking, By Operating Parameters
  • 13.4. Key Strategic Developments (Mergers, Acquisitions, Partnerships, etc.)

14. Impact of Escalating Geopolitical Tensions on Global Antibody and Recombinant Protein CDMO Market

15. Company Profiles (Company Overview, Financial Matrix, Competitive Landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook, and SWOT Analysis)

  • 15.1. Batavia Biosciences
  • 15.2. Grifols
  • 15.3. Cerbios-Pharma SA
  • 15.4. HALIX
  • 15.5. Biovian Oy
  • 15.6. Catalent
  • 15.7. Goodwin Biotechnology
  • 15.8. Cerbios-Pharma SA
  • 15.9. Gene Universal Inc.
  • 15.10. Eurogentec
  • 15.11. MabPlex International
  • 15.12. Etinpro (Beijing) Co
  • 15.13. Other Prominent Players

16. Key Strategic Recommendations

17. Research Methodology

  • 17.1. Qualitative Research
    • 17.1.1. Primary & Secondary Research
  • 17.2. Quantitative Research
  • 17.3. Market Breakdown & Data Triangulation
    • 17.3.1. Secondary Research
    • 17.3.2. Primary Research
  • 17.4. Breakdown of Primary Research Respondents, By Region
  • 17.5. Assumptions & Limitations

*Financial information of non-listed companies can be provided as per availability.

**The segmentation and the companies are subject to modifications based on in-depth secondary research for the final deliverable